Medical record abstraction for eligible SJLIFE participants is performed using a protocol similar to that utilized in the CCSS.40 (link) This includes abstraction of all chemotherapy received, including cumulative doses for 32 specific chemotherapeutic agents [5-Azacytidine, Bleomycin, Busulfan, Carboplatin, Carmustine, Cisplatin, Cyclophosphamide (IV, PO), Cytarabine (IV, IM, IT, SubQ), Dacarbazine, Dactinomycin, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide (IV, PO), Fludarabine, Fluorouracil, Hydroxyurea, Idarubicin, Ifosfamide, L-Asparaginase, Lomustine, Melphalan, Methotrexate (IV, IM, IT), Nitrogen Mustard, Prednisone, Procarbazine, Teniposide, Thioguanine, Thiotepa, Tretinoin, Vinblastine, Vincristine], surgical procedures, and radiation treatment fields, dose, and energy source. To assure comprehensive ascertainment of health outcomes related to specific treatment exposures, key health events, especially life-threatening organ toxicity, and subsequent malignancies are also obtained. The sources of this information include medical records, Cancer Registry follow-up, and/or contact with next-of-kin for SJCRH patients who survived 10 or more years from diagnosis but subsequently died or are lost to follow-up.